Alexion Pharmaceuticals Inc. Release: FDA Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG)

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.

Help employers find you! Check out all the jobs and post your resume.